Aim: To evaluate peritoneal resorption capacity for lipopolysaccharide (LPS) and interleukin-6 (IL-6) in a model of chemical peritonitis. Methods: Zymosan peritonitis was induced in anesthetized rats. LPS was injected intraperitoneally to different groups at 4 h (n = 10), 8 h (n = 9), 12 h (n = 9), and 24 h (n = 9) after peritonitis and to a control group (n = 8). Similarly, IL-6 was injected intraperitoneally to different groups at 4 h (n = 9), 8 h (n = 10), 12 h (n = 10), and 24 h (n = 10) after peritonitis, and to a control group (n = 10). Plasma levels of LPS or IL-6 were measured immediately after intraperitoneal injections of LPS or IL-6, respectively, and at 5, 15, 30, 45, and 60 min later. Results: There was no change over time in plasma LPS levels in the groups receiving LPS intraperitoneally (p = 0.4). There was highly significant change over time in the IL-6 level in the studied time periods in the groups receiving IL-6 intraperitoneally (p < 0.0001). There was an increase in the plasma IL-6 level when sampled at 4 h after peritonitis. Conclusion: There was a reduction of resorption capacity of inflamed peritoneum for inflammatory mediators in acute chemical peritonitis.

Keywords:
Resorption, Peritoneum, Experimental peritonitis, Inflammatory mediators, Peritonitis, Lipopolysaccharide, Interleukin-6, Zymosan
1.
Hall JC, Heel KA, Papadimitriou JM, Platell C: The pathobiology of peritonitis. Gastroenterology 1998;114:185–196.
2.
Hunsicker A, Kullich W, Weissenhofer W, et al: Correlations between LPS, interferon-γ, biopterin and serum phospholipase A2 activities during lethal Gram-negative sepsis in rats. Eur J Surg 1997;163:379–385.
3.
Buttenschoen K, Buttenschoen DC, Berger D, et al: Endotoxemia and acute-phase proteins in major abdominal surgery. Am J Surg 2001;181:36–43.
4.
Yao V, Cooper D, McCauley R, Platell C, Hall J: Bacterial translocation in a non-lethal rat model of peritonitis. Colorectal Dis 2001;3:338–344.
5.
Gurleyik E, Gurleyik G, Unalmiser S: Blockade of transdiaphragmatic lymphatic absorption reduced systemic inflammatory response syndrome during experimental peritonitis: evaluation with body oxygen kinetics in rats. Eur J Surg 1996;162:729–734.
6.
Olofsson P, Nylander G, Olsson P: LPS: routes of transport in experimental peritonitis. Am J Surg 1986;151:443–446.
7.
Carlsson O, Rippe B: Peritoneal lymphatic absorption and solute exchange during zymosan-induced peritonitis in the rat. Am J Physiol 1999;277:H1107–H1112.
8.
Berger D, Buttenschoen K: Management of abdominal sepsis. Langenbecks Arch Surg 1998;383:35–43.
9.
Rosman C, Wubbels GH, Manson WL, Bleichrodt RP: Selective decontamination of the digestive tract prevents secondary infection of the abdominal cavity, and endotoxemia and mortality in sterile peritonitis in laboratory rats. Crit Care Med 1992;20:1699–1704.
10.
Kolaczkowska E, Shahzidi S, Seljelid R, et al: Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes. Inflammation 2002;26:61–71.
11.
Goris RJ, van Bebber IP, Mollen RM, Koopman JP: Does selective decontamination of the gastrointestinal tract prevent multiple organ failure? An experimental study. Arch Surg 1991;126:561–565.
12.
Ludbrook J: Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303–311.
13.
Munro BH: Repeated measures analysis of variance; in Munro BH (ed): Statistical Methods for Health Care Research. Baltimore, Lippincott, 2001, pp 201–221.
14.
Burdon D, Tiedje T, Pfeffer K, et al: The role of tumor necrosis factor in the development of multiple organ failure in a murine model. Crit Care Med 2000;28:1962–1967.
15.
Parker SJ, Watkins PE: Experimental models of Gram-negative sepsis. Br J Surg 2001;88:22–30.
16.
Cooper D, Yao V, McCauley R, et al: A low-morbidity murine model of peritonitis. Dis Colon Rectum 2002;45:394–400.
17.
Cuzzocrea S, de Sarro G, Costantino G, et al: Role of interleukin-6 in a non-septic shock model induced by zymosan. Eur Cytokine Netw 1999;10:191–203.
18.
Mizuno M, Ito Y, Hepburn N, et al: Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. J Immunol 2009;183:1403–1412.
19.
Fujimoto M: Experimental study on the effect of various types of peritonitis and elevation of intra-abdominal pressure on LPS absorption. Nippon Geka Gakkai Zasshi 1989;90:1989–1999.
20.
Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 2003;31:2228–2237.
21.
Cheadle WG, Spain DA: The continuing challenge of intra-abdominal infection. Am J Surg 2003;186:15S–22S.
22.
Dellinger EP, Wertz MJ, Meakins JL, et al: Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 1985;120:21–29.
23.
Van Deventer SJ, ten Cate JW, Tytgat GN: Intestinal endotoxemia. Clinical significance. Gastroenterology 1988;94:825–831.
24.
Qin HL, Shen TY, Gao ZG, et al: Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. World J Gastroenterol 2005;11:2591–2596.
25.
Beale RJ, Sherry T, Lei K, et al: Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. Crit Care Med 2008;36:131–144.
26.
Mamedov AM, Gamzaev SM, Shikhammedov NA, et al: The significance of intestinal decompression and lavage in the treatment of ileus and peritonitis (in Russian). Klin Khir 2007;8:12–14.
27.
Avakov VE, Ogai VC, Tashmukhamedov BA, et al: A complex method of endotoxemia assessment in peritonitis in the process of corrective therapy (in Russian). Anesteziol Reanimatol 1989;3:63–66.
28.
Scheiermann P, Hoegl S, Revermann M, et al: Cecal ligation and incision: an acute onset model of severe sepsis in rats. J Surg Res 2009;151:132–137.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.